HDAC2 and metabolic dysfunction-associated steatotic liver disease: In MASLD patients, downregulation of the GLP-1 receptor in the liver is observed, with butyrate supplementation in MASLD mice enhancing GLP-1 receptor expression by inhibiting HDAC-2, consequently promoting energy metabolism and inhibiting lipid accumulation [338].